Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (DE:GE9)
XETRA:GE9
GE9 Stock Chart & Stats
€290.70
€3.40(1.61%)
At close: 4:00 PM EST
€290.70
€3.40(1.61%)
Day’s Range― - ―
52-Week Range€155.80 - €299.90
Previous CloseN/A
Volume0.00
Average Volume (3M)115.00
Market Cap
€18.55B
Enterprise Value€63.39B
Total Cash (Recent Filing)€3.23B
Total Debt (Recent Filing)€143.00M
Price to Earnings (P/E)13.6
Beta0.48
Next Earnings
Feb 05, 2026EPS Estimate
3.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.55
Shares Outstanding64,238,410
10 Day Avg. Volume196
30 Day Avg. Volume115
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€313.40Price Target Upside7.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy Of PetosemtamabAnalyst highlights that petosemtamab produces markedly improved tumor responses and survival signals versus current standards, supporting a potential chemo-free option that could reshape treatment pathways.
Commercial Catalysts And Financial VisibilityGenmab's fileable data lead and three material FY26 catalysts are expected to provide clearer visibility into EBIT growth after Darzalex loses exclusivity, supported by heavy SG&A investment to commercialize new products.
Rina-S Safety And Dosing ProfileAnalyst describes Rina-S as showing broad activity across patient groups with durable responses and a favorable safety profile that lacks lung or eye toxicity and offers more convenient dosing than several rivals.
Bears Say
Acquisition Dilution And Near-term Earnings ImpactAnalyst warns the proposed Merus acquisition is projected to be dilutive to reported 2026 and 2027 EPS and may not be accretive until 2031, creating short-term shareholder value pressure.
Competitive Risk To Epkinly In Frontline DLBCLAnalyst points out that growing competition in frontline DLBCL could complicate Epkinly's market opportunity despite promising clinical data, pressuring market share and uptake.
Strategic M&A Overhang And Patent Cliff RiskAnalyst cautions that reliance on acquisitions could steepen the company's patent cliff and require frequent piecemeal deals, creating a persistent strategic overhang for the shares.
Genmab A/S News
GE9 FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was €155.80 and its highest was €299.90 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is €18.55B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Feb 05, 2026 which is in 20 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Nov 06, 2025. The company reported €5.55 earnings per share for the quarter, beating the consensus estimate of €4.176 by €1.374.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 3.7.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 64,238,410 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of €5.55 in its last earnings report, beating expectations of €4.176. Following the earnings report the stock price went down -1.691%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in DE:GE9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
GE9 Stock 12 Month Forecast
Average Price Target
€313.40
▲(7.81% Upside)
Technical Analysis
Options Prices
Currently, No data available
---